



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Frontiers Editorial Office
✉ research.integrity@frontiersin.org

RECEIVED 22 September 2023

ACCEPTED 27 September 2023

PUBLISHED 10 October 2023

CITATION

Frontiers Editorial Office (2023) Retraction:
MicroRNA-326 functions as a tumor
suppressor in breast cancer by targeting
ErbB/PI3K signaling pathway.
Front. Oncol. 13:1298871.
doi: 10.3389/fonc.2023.1298871

COPYRIGHT

© 2023 Frontiers Editorial Office. This is an
open-access article distributed under the
terms of the [Creative Commons Attribution
License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that
the original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Retraction: MicroRNA-326 functions as a tumor suppressor in breast cancer by targeting ErbB/PI3K signaling pathway

Frontiers Editorial Office*

A Retraction of the Original Research Article

[MicroRNA-326 functions as a tumor suppressor in breast cancer by targeting ErbB/PI3K signaling pathway](#)

by Ghaemi Z, Soltani BM and Mowla SJ (2019) *Front. Oncol.* 9:653. doi: 10.3389/fonc.2019.00653

Following publication, concerns were raised regarding the validity of the data in the article. The authors failed to provide the raw data and a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers' policies. Given the concerns about the validity of the data, and the lack of raw data, the editors no longer have confidence in the findings presented in the article. This retraction was approved by the Chief Editors of Frontiers in Oncology.

The authors did not agree with the retraction.